Creative Medical Technology Holdings, Inc. revenue
Creative Medical Technology Holdings, Inc.'s revenue was $6,000 in fiscal 2025, down 45.5% on the year before. Since fiscal 2017 ($4,800) it has grown at a compound 2.8% a year. Over the last twelve months it was $3,000.
Revenue history
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 124 | 166 | 165 | 88 | 89 | 9 | 11 | 6 | 3 |
| Growth on the year before | — | — | — | — | — | — | — | — | +>999% | +33.0% | −0.6% | −46.7% | +1.0% | −89.8% | +22.2% | −45.5% | — |
| Gross profit | — | — | — | — | — | — | 0 | −3 | 54 | 120 | 114 | 40 | 60 | 5 | 7 | 4 | 2 |
| Gross margin | — | — | — | — | — | — | — | −66.7% | 43.4% | 72.5% | 69.2% | 45.4% | 67.8% | 60.0% | 60.0% | 63.4% | 66.9% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Creative Medical Technology Holdings, Inc. | $3,000 | -50.0% | -65.6% |
| Lyell Immunopharma, Inc. | $27,000 | -55.0% | -91.8% |
| AIM Immunotech Inc. | $95,000 | -21.5% | -17.3% |
| Ibio, Inc. | $100,000 | -75.0% | -62.4% |
| Lisata Therapeutics, Inc. | $100,000 | -90.7% | — |
| Celldex Therapeutics, Inc. | $158,000 | -97.3% | -63.5% |
Compare with peers
- Lyell Immunopharma, Inc. revenue
- AIM Immunotech Inc. revenue
- Ibio, Inc. revenue
- Lisata Therapeutics, Inc. revenue
- Celldex Therapeutics, Inc. revenue
Head to head: CELZ vs LYELAIM vs CELZCELZ vs IBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies